Analysts Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) PT at $4.25

Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) have been assigned an average recommendation of “Buy” from the five ratings firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $4.00.

A number of equities analysts recently commented on MRSN shares. William Blair initiated coverage on shares of Mersana Therapeutics in a research note on Thursday, February 6th. They set an “outperform” rating for the company. Wedbush restated an “outperform” rating and set a $4.00 target price on shares of Mersana Therapeutics in a research report on Monday, March 3rd.

Hedge Funds Weigh In On Mersana Therapeutics

A number of hedge funds have recently added to or reduced their stakes in MRSN. US Bancorp DE purchased a new stake in shares of Mersana Therapeutics in the third quarter valued at approximately $31,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Mersana Therapeutics in the 3rd quarter worth $34,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Mersana Therapeutics during the 4th quarter worth $37,000. Intech Investment Management LLC purchased a new position in shares of Mersana Therapeutics during the third quarter valued at $52,000. Finally, Quarry LP bought a new stake in shares of Mersana Therapeutics in the third quarter valued at about $57,000. 93.92% of the stock is currently owned by institutional investors.

Mersana Therapeutics Price Performance

NASDAQ:MRSN opened at $0.46 on Thursday. The firm has a market capitalization of $57.21 million, a price-to-earnings ratio of -0.75 and a beta of 1.67. The company has a debt-to-equity ratio of 13.35, a current ratio of 2.35 and a quick ratio of 2.35. The business has a 50 day simple moving average of $0.59 and a 200-day simple moving average of $1.48. Mersana Therapeutics has a 1 year low of $0.43 and a 1 year high of $5.11.

Mersana Therapeutics (NASDAQ:MRSN) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. The company had revenue of $16.36 million during the quarter, compared to the consensus estimate of $7.71 million. Equities analysts forecast that Mersana Therapeutics will post -0.62 EPS for the current year.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.